BRPI0808570B8 - processo para a preparação de inibidores de glyt-1 - Google Patents

processo para a preparação de inibidores de glyt-1

Info

Publication number
BRPI0808570B8
BRPI0808570B8 BRPI0808570A BRPI0808570A BRPI0808570B8 BR PI0808570 B8 BRPI0808570 B8 BR PI0808570B8 BR PI0808570 A BRPI0808570 A BR PI0808570A BR PI0808570 A BRPI0808570 A BR PI0808570A BR PI0808570 B8 BRPI0808570 B8 BR PI0808570B8
Authority
BR
Brazil
Prior art keywords
compound
formula
glyt
inhibitors
preparing
Prior art date
Application number
BRPI0808570A
Other languages
English (en)
Portuguese (pt)
Inventor
Pfleger Christophe
Waldmeier Pius
Wang Shaoning
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0808570A2 publication Critical patent/BRPI0808570A2/pt
Publication of BRPI0808570B1 publication Critical patent/BRPI0808570B1/pt
Publication of BRPI0808570B8 publication Critical patent/BRPI0808570B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0808570A 2007-03-05 2008-02-25 processo para a preparação de inibidores de glyt-1 BRPI0808570B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103485 2007-03-05
EP07103485.4 2007-03-05
PCT/EP2008/052244 WO2008107334A2 (en) 2007-03-05 2008-02-25 Process for the synthesis of glyt-1 inhibitors

Publications (3)

Publication Number Publication Date
BRPI0808570A2 BRPI0808570A2 (pt) 2014-09-02
BRPI0808570B1 BRPI0808570B1 (pt) 2020-09-15
BRPI0808570B8 true BRPI0808570B8 (pt) 2021-05-25

Family

ID=39469606

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808570A BRPI0808570B8 (pt) 2007-03-05 2008-02-25 processo para a preparação de inibidores de glyt-1

Country Status (13)

Country Link
US (1) US7812161B2 (enExample)
EP (1) EP2131843B1 (enExample)
JP (1) JP4745446B2 (enExample)
KR (1) KR101143073B1 (enExample)
CN (1) CN101622000B (enExample)
AT (1) ATE532516T1 (enExample)
AU (1) AU2008223915B2 (enExample)
BR (1) BRPI0808570B8 (enExample)
CA (1) CA2678630C (enExample)
ES (1) ES2375585T3 (enExample)
IL (1) IL200323A (enExample)
MX (1) MX2009009065A (enExample)
WO (1) WO2008107334A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656474B2 (ja) 2010-06-28 2015-01-21 関東化学株式会社 脂肪族光学活性フルオロアルコールの製造方法
CN104628679B (zh) * 2013-11-08 2018-02-09 江苏恩华药业股份有限公司 Bitopertin的合成方法及其中间体
CN106397312B (zh) * 2015-07-31 2020-03-24 广东东阳光药业有限公司 一种制备glyt-1抑制剂的方法
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
KR20230088761A (ko) 2020-10-13 2023-06-20 베링거 인겔하임 인터내셔날 게엠베하 재가공하는 방법
WO2024042043A1 (en) 2022-08-24 2024-02-29 Boehringer Ingelheim International Gmbh A scalable process for the preparation of a glyt-1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4480102A (en) * 1982-07-23 1984-10-30 The Dow Chemical Company 2,3-Difluoro-5-(trifluoromethyl)pyridine and methods of making and using the same
ES2061953T3 (es) * 1988-11-24 1994-12-16 Akzo Nv Un procedimiento para preparar una composicion farmaceutica.
DE4235155A1 (de) * 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
DE69906059D1 (de) * 1998-04-20 2003-04-24 Fujisawa Pharmaceutical Co Anthranilsäurederivate als inhibitoren der c-gmp-phosphodiesterase
DE10112040A1 (de) 2001-03-14 2002-10-02 Aventis Pharma Gmbh Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
NZ544820A (en) * 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
PL1828154T3 (pl) * 2004-12-09 2009-10-30 Hoffmann La Roche Pochodne fenylopiperazynometanonu
CA2593453A1 (en) * 2005-01-06 2006-07-13 F. Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
ATE472327T1 (de) * 2005-01-07 2010-07-15 Hoffmann La Roche Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
KR100946461B1 (ko) * 2005-07-08 2010-03-10 에프. 호프만-라 로슈 아게 1,1,1-트라이플루오로아세톤의 비대칭 환원

Also Published As

Publication number Publication date
US20080221327A1 (en) 2008-09-11
CA2678630A1 (en) 2008-09-12
JP2010520251A (ja) 2010-06-10
CN101622000A (zh) 2010-01-06
CN101622000B (zh) 2012-07-04
EP2131843B1 (en) 2011-11-09
KR20090110368A (ko) 2009-10-21
ES2375585T3 (es) 2012-03-02
US7812161B2 (en) 2010-10-12
IL200323A (en) 2013-11-28
CA2678630C (en) 2015-04-14
MX2009009065A (es) 2009-08-31
KR101143073B1 (ko) 2012-05-08
EP2131843A2 (en) 2009-12-16
ATE532516T1 (de) 2011-11-15
IL200323A0 (en) 2010-04-29
WO2008107334A3 (en) 2008-10-23
AU2008223915B2 (en) 2013-05-02
BRPI0808570B1 (pt) 2020-09-15
JP4745446B2 (ja) 2011-08-10
AU2008223915A1 (en) 2008-09-12
WO2008107334A2 (en) 2008-09-12
BRPI0808570A2 (pt) 2014-09-02

Similar Documents

Publication Publication Date Title
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
BRPI0813284A8 (pt) Processo para a preparação de um composto da fórmula (i) e composto
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
UA111594C2 (uk) Гетероциклічна сполука і її застосування
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
AR062504A1 (es) Procedimientos para preparar acidos d,l-2hidroxi-4-alquiltiobutiricos
BR112013002925A2 (pt) processo para a síntese de ácido 2,5-furandicarboxílico
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
BR112014004210A2 (pt) processo para a preparação de derivados de diamida do ácido antranílico substituídos com tetrazole por reação de benzoxazinonas com aminas
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
BR112013001721A2 (pt) processo de síntese de compostos de ureia substituída
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
IL200323A0 (en) Synthesis of glyt-1 inhibitors
UA104420C2 (uk) Застосування похідних глутарової кислоти або їх фармацевтично прийнятних солей як протиаритмічних засобів
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
BRPI0907052B8 (pt) processo para a preparação de compostos
BR112012009611A2 (pt) ''processo para a preparação de um composto de fómula (i)''
WO2008145673A3 (de) Verfahren zur herstellung von 4-formylaminopiperidinderivaten
BRPI0508430A (pt) processo para a preparação de inibidores da triptase
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
BRPI0909752B8 (pt) processos para a produção de sulfonilpirróis como inibidores de hdac e de uma composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF